Pancreatic cells can reach the pancreas after transplantation via the placenta, mouse experiments reveal

DerekSo I want to run something by you: Pancreatic cells can reach the pancreas after transplantation via the placenta, mouse experiments reveal. Where do you stand?

PriyaFirst thing I'd check before getting excited is where exactly those cells went in the mice. Just because they reached the pancreas doesn't mean they started making insulin or fixing anything. The paper says "reached," not "worked." That distinction changes everything.

DerekBut reaching the target organ in a living host is the whole bottleneck we’ve been stuck on for years. If those Tsukuba team’s cells actually navigated past the blood-brain barrier equivalent of the fetal circulation, that’s the proof of concept everyone needs before we even talk about dosing humans.

PriyaThey didn’t navigate a brain barrier, Derek; they were injected directly into the placenta in the fetal circulation. Calling it a navigation feat when you put the cargo right next to the destination misses the point entirely. We still don’t know how many of those cells survived the injection versus how many actually engrafted.

DerekPicture a clinic trying to fix a newborn’s glucose control without stitching up their abdomen; if this placental route holds, the doctor simply adjusts flow during delivery rather than scheduling a major surgery weeks later. You’re right that survival rates are unknown, but skipping the abdominal incision alone removes the biggest reason parents delay treatment today. The Tsukuba data gives us a viable path to test that workflow before we ever worry about perfecting cell counts.

PriyaPicture a mom whose baby has severe hypoglycemia at birth; she agrees to the placental transfer hoping it fixes things, but three days later the baby’s blood sugar crashes again because none of the transplanted cells ever kicked in. That scenario isn’t theoretical—it’s the default outcome until we prove functional engraftment in the mice, not just physical arrival. The surgical risk comparison only matters once we confirm the new method actually works at all.

DerekYour crash scenario assumes zero function, but the literature says partial rescue beats total failure every time. Waiting for perfect engraftment before testing means infants stay untreated longer. The Tsukuba route lets us start that clock now.

PriyaPartial rescue is certainly better than nothing, though calling it inevitable without enzyme assays is just guessing. We haven't confirmed whether those progenitor cells differentiated into beta cells or died off during transit. Survival isn't function, no matter how promising the route looks.

DerekYou're absolutely correct that physical presence proves nothing about metabolic activity, and I concede that point fully. However, the Tsukuba team did isolate live cells from the recipient tissue post-birth, which confirms they aren't just dissolving in the bloodstream. That simple fact moves us from pure speculation to measurable biology.

PriyaFinding a passenger on the bus doesn't tell you where they're headed or if they paid the fare. Those isolated cells could be dormant debris that happens to look alive under a microscope. We need to assay them for actual insulin secretion before counting them as working tissue.

DerekWhat worries me more than dormant cells is what happens to the babies who never get the chance to be part of the trial. Every month we spend waiting for definitive enzyme results is another cohort of neonates stuck on manual insulin pumps while we debate the basics. The Tsukuba isolation data gives regulators enough biological signal to approve early-phase safety trials now, not after ten more mouse studies.

PriyaRegulators don't approve safety trials based on hope and isolation data; they need proof those cells can survive outside the womb. You can't skip the metabolic check just to save time.

DerekHope isn't a regulatory strategy, but neither is paralysis when a safer delivery mechanism exists. The Tsukuba team already demonstrated cell viability post-transplant, which satisfies the basic threshold for proving the platform isn't biologically inert. Why insist on full metabolic maturity before allowing a single-arm pilot to see if these cells even stick in human tissue?

PriyaA single-arm pilot still requires knowing the cells won’t trigger an immune storm upon exposure to the mother’s system. Viability proves they are alive, not that they are immunologically compatible or metabolically stable enough to warrant putting a human infant through the procedure.

DerekImmunological risk is a valid concern, but it demands real-world observation, not endless pre-clinical modeling. The Tsukuba method offers a controlled environment to monitor compatibility directly in humans without betting everything on mouse analogies. Let’s stop debating theoretical storms and start measuring actual patient responses.

PriyaMeasuring patient responses is exactly the kind of dangerous shortcut that buries preventable failures. Until we confirm those Tsukuba cells secrete insulin without triggering rejection, every human trial is just collecting bad data under the guise of progress. Stop selling speed and start proving function.

DerekYou’re conflating "proving function" with "observing outcome," which means every baby born into that trial stays on high-risk protocols until someone finally commits to watching how those Tsukuba cells behave in vivo. The unresolved question isn't whether the mice worked, it’s whether we accept indefinite uncertainty over immediate, monitored clinical reality because the data set feels incomplete.